

Molnupiravir Use Among Patients With COVID-19 in Real-World Settings: A Systematic Literature Review

Julia Richmond DiBello¹, Valerie T. Raziano (0000-0003-4710-8070)², Xinyue Liu (0000-0003-1610-1263)¹, Amy Puenpatom², Kathryn Peebles (0000-0002-2095-7446)¹, Nazleen F. Khan (0000-0003-4012-6671)¹, and Deanna D. Hill¹

¹ Biostatistics and Research Decision Sciences (BARDS), Epidemiology, Merck & Co., Inc., Rahway, NJ, USA; ² Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, USA

Corresponding author:

Valerie Raziano
351 N Sumneytown Pike
North Wales, PA 19454
Merck & Co., Inc., USA
267-305-4794
Email: Valerie.raziano@merck.com

SUPPLEMENTARY MATERIAL

Table S1. Search terms used to identify potentially eligible studies from the Embase database

Study variable	Search terms
Intervention	'molnupiravir'/exp OR '4 oxime 5` (2 methylpropanoate) uridine' OR '4 oxime 5` isobutyrate) uridine' OR '[3, 4 dihydroxy 5 [4 (hydroxyimino) 2 oxo 1 pyrimidinyl] 2 oxolanyl] methyl 2 methylpropanoate' OR '[3, 4 dihydroxy 5 [4 (hydroxyimino) 2 oxo 1 pyrimidinyl] 2 oxolanyl] methyl isobutyrate' OR '[3, 4 dihydroxy 5 [4 (hydroxyimino) 2 oxo 1 pyrimidinyl] 2 tetrahydrofuranyl] methyl isobutyrate' OR '[3, 4 dihydroxy 5 [4 (hydroxyimino) 2 oxopyrimidin 1 (2h) yl] tetrahydrofuran 2 yl] methyl isobutyrate' OR '[3, 4 dihydroxy 5 [4 (hydroxyimino) 2 oxopyrimidin 1 yl] oxolan 2 yl] methyl 2 methylpropanoate' OR '[3, 4 dihydroxy 5 [4 (hydroxyimino) 2 oxopyrimidin 1 yl] oxolan 2 yl] methyl isobutyrate' OR '[3, 4 dihydroxy 5 [4 (hydroxyimino) 2 oxopyrimidin 1 yl] tetrahydrofuran 2 yl] methyl isobutyrate' OR 'beta dextro n4 hydroxycytidine 5` isopropyl ester' OR 'eidd 2801' OR 'eidd2801' OR 'lagevrio' OR 'mk 4482' OR 'mk4482' OR 'molnupiravir' OR 'n4 hydroxycytidine 5` (2 methylpropanoate)' OR 'n4 hydroxycytidine 5` isobutyrate' OR 'n4 hydroxycytidinen 5` (2 propyl) ester' OR 'n4 hydroxycytidinen 5` isopropyl ester' OR 'uridine 5` (2 methylpropanoate) 4 oxime' OR 'uridine 5` methylpropanoate 4 oxime') OR ('molnupiravir'/exp OR molnupiravir)
Study type	'real world' OR 'cohort analysis'/de OR 'comparative effectiveness'/de OR comparative study'/de OR 'controlled study'/de OR 'logistic regression analysis'/de OR 'longitudinal study'/de OR 'meta analysis'/de OR 'meta analysis topic'/de OR 'multicenter study'/de OR 'multicenter study topic'/de OR 'multivariate logistic regression analysis'/de OR 'observational study'/de OR 'postmarketing surveillance'/de OR 'prospective study'/de OR 'retrospective study'/de OR 'secondary analysis'/de
Limit terms	Human; time period 2021–2023

The Embase search was conducted as (all intervention search terms) AND (all study type search terms)

AND (all limit terms). The Scopus database search was conducted with the following search terms: (TITLE-ABS-KEY (molnupiravir OR lagevrio)) AND (real AND world) AND (LIMIT-TO (PUBYEAR, 2023) OR LIMIT-TO (PUBYEAR, 2022) OR LIMIT-TO (PUBYEAR, 2021)) AND (LIMIT-TO (SUBJAREA, "MEDI") OR LIMIT-TO (SUBJAREA, "PHAR") OR LIMIT-TO (SUBJAREA, "IMMU") OR LIMIT-TO (SUBJAREA, "NEUR")).

